Challenges in The Management ofKallmann Syndrome : A Case Report
DOI:
https://doi.org/10.66266/inajemd.v2i2.63Keywords:
Kallmann syndrome, small penis, gynecomastia, testosteron undecanoate, surgeryAbstract
Background: Kallman syndrome is combined disorder of hypogonadotropic hypogonadism and anosmia. Incidence of congenital hypogonadotropic hypogonadism is 1-10:100,000 live
births, and approximately 2/3 and 1/3 of cases are caused by Kallmann syndrome and idiopathic hypogonadotropic hypogonadism, respectively.
Case illustration: We report a man, 35 years old, with complaints of small penis, small voice, impaired smell, gynecomastia, narrowing of visual field, mustache not growing, little pubic and armpit hair. Patient underwent surgery on both breasts with histopathological results of gynecomastia, no malignancy. Testicular ultrasound results showed bilateral testicular atrophy. Laboratory results showed karyotype 46XY, Follicle-stimulating hormone 1.79 mIU/mL, Luteinizing hormone 1.49 mIU/mL, testosterone <0.03 ng/mL, estradiol 5.0 pg/mL, prolactin 6.75 ng/mL and prostate-specific antigen 0.473 ng/mL. Head CT scan imaging showed bilateral otitis media, mastoiditis and sinusitis. Patient was diagnosed Kallmann syndrome, anxiety and depression symptoms (ADS) chronic tubotympanic suppurative otitis media, sinusitis, oculus dexter and sinister hemianopsia. Patient was treated with testosterone undecanoate injection 1000 mg IM every 3 months, levofloxacin 500 mg PO once daily, avamys nasal spray twice daily.
Discussion: Symptoms of Kallman syndrome can include absent or incomplete pubertal development, anosmia or hyposmia, and low sex steroid levels. KAL1 gene mutations cause Gonadotropin-releasing hormone (GnRH) deficiency, associated with Kallmann syndrome. Testosteron replacement is indicated for men who already have children or have no desire for children. Surgery should be considered as the last option in patients with considerable discomfort, psychological stress, cosmetic problems, long‑standing gynecomastia (>12 months) and suspected malignancy.
Conclusion: The aim of testosterone therapy is to reverse the symptoms of hypogonadism, and surgery is last option in patients with considerable discomfort.
Downloads
References
1. Dode, C., and Hardelin, J. P, 2009, Kallman
syndrome, European Journal of Human Genetics,
17: 139–146, doi:10.1038/ejhg.2008.206.
2. Fraietta, R., Zylberstejn, D.S., EstevesI, S.C.,
2013, Hypogonadotropic hypogonadism
revisited, Clinics, 68 (51): 81-88, doi. 10.6061/
clinics/2013(Sup01)09.
3. Young, J., Xu, C., Papadakis, G. E., Acierno, J. S.,
Maione, L., Hietamaki, J., Raivio, T., Pitteloud,
N., 2019, Clinical management of congenital
hypogonadotropic hypogonadism, Endocrine
Reviews, 40: 669-710, doi. 10.1210/er.2018-
00116.
4. Laitinem, E. M., Vaaralahti, K.,Incidence, Tommiska,
J., Eklund, E., Tervaniemi, M., Valanne, L., Raivio,
T., 2011, Phenotypic features and molecular
genetics of Kallmann syndrome in Finland,
Orphanet Journal of Rare Diseases, 6: 41.
5. Cuhaci, N., Polat, S. B., Evranos, B., Ersoy, R., Cakir,
B., 2014, Gynecomastia: Clinical evaluation and
management, Indian Journal of Endocrinology and
Metabolism, vol 18: 150-158, doi.10.4103/2230-
8210.129104.
6. Kanakis, G. A., Nordkap, L., Bang, A. K., Calogero,
A. E., Artfai, G. B., Corona, G., Forti, G., Toppari,
J., Goulis, D. G., Jorgensen, N., 2019, EAA clinical
practice guidelines- gynecomastia evaluation
and management, American Society of Andrology
and European Academy of Andrology, 7: 778-793,
doi.10.1111/andr.12636.
7. Sagi, S. V., Joshi, H., Whiles, E., Hikmat, M., Puthi,
V. R., MacDougall, J., Spiden, S.. L., Fuller, G., Park,
S. M., Oyibo, S. O., 2020, Normosmic idiopathic
hypogonadotropic hypogonadism due to a novel
GNRH1 variant in two siblings, Endocrinology
Diabetes and Metabolism, doi.10.1530/EDM-
19-0145.
8. Liu, Y., and Zhi, X., 2021, Advances in Genetic
Diagnosis of Kallmann Syndrome and Genetic
Interruption, Reproductive Sciences, 6 :1-13, doi.
org/10.1007/s43032-021- 00638-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD) the right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
© Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD). Published by the Indonesian Society of Endocrinology (PERKENI).


